Structure Therapeutics reports positive Phase 2a data for obesity drug GSBR-1290

Structure Therapeutics Inc.

GSBR-1290 achieved placebo-adjusted mean weight loss of 6.2% (p<0.0001) in Phase 2a obesity study at 12 weeks.
Capsule to tablet PK study showed up to 6.9% placebo-adjusted weight loss (p<0.0001) with new tablet formulation.
67% of GSBR-1290 treated participants achieved ≥6% weight loss and 33% ≥10% loss vs 0% for placebo.
Adverse events were GI-related; discontinuations 5% in Phase 2a and 11% in PK study; no liver injury.
Phase 2b obesity study expected to begin Q4 2024 with ~300 participants using tablet formulation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.